These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 15115135

  • 21. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
    Klein NP, Shepard J, Bedell L, Odrljin T, Dull P.
    Vaccine; 2012 Jun 06; 30(26):3929-36. PubMed ID: 22504039
    [Abstract] [Full Text] [Related]

  • 22. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ, Protocol 014 Study Group for ProQuad.
    Pediatrics; 2006 Feb 06; 117(2):265-72. PubMed ID: 16452343
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.
    Pediatrics; 1986 Oct 06; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.
    Stück B, Stehr K, Bock HL.
    Asian Pac J Allergy Immunol; 2002 Jun 06; 20(2):113-20. PubMed ID: 12403196
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O.
    BMJ Open; 2015 Sep 11; 5(9):e007202. PubMed ID: 26362659
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
    Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A.
    BMC Med; 2009 Apr 14; 7():16. PubMed ID: 19366435
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
    Santos EMD, Noronha TG, Alves IS, Cruz RLS, Ferroco CLV, Brum RC, Oliveira PMN, Siqueira MM, Lima MC, Ramos FLP, Bragagnolo CM, Camacho LAB, Maia MLS.
    Mem Inst Oswaldo Cruz; 2019 Mar 07; 114():e180517. PubMed ID: 30843921
    [Abstract] [Full Text] [Related]

  • 39. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX.
    Shinefield HR, Black SB, Staehle BO, Adelman T, Ensor K, Ngai A, White CJ, Bird SR, Matthews H, Kuter BJ.
    Pediatr Infect Dis J; 1998 Nov 07; 17(11):980-5. PubMed ID: 9849978
    [Abstract] [Full Text] [Related]

  • 40. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S, Friedland LR, Schuind A, Howe B, GlaxoSmithKline DTaP-IPV Vaccine Study Group.
    Vaccine; 2006 Aug 28; 24(35-36):6163-71. PubMed ID: 16759769
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.